Celldex Therapeutics Q3 2024 Financial Update

TL;DR

Celldex Q3: Assets $55.9M, Liabilities $66.3M. Financials filed.

AI Summary

Celldex Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $55.9 million and total liabilities of $66.3 million as of September 30, 2024. The filing details financial performance and operational updates for the third quarter of 2024.

Why It Matters

This filing provides investors with a snapshot of Celldex Therapeutics' financial health and operational status as of the end of the third quarter of 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — The company's liabilities exceed its assets, indicating potential financial strain.

Key Numbers

• $55.9M — Total Assets (As of September 30, 2024, indicating the company's resources.)
• $66.3M — Total Liabilities (As of September 30, 2024, representing the company's obligations.)

Key Players & Entities

• Celldex Therapeutics, Inc. (company) — Filer of the 10-Q report.
• 2024-09-30 (date) — End of the reporting period for the 10-Q.
• $55.9 million (dollar_amount) — Total assets as of September 30, 2024.
• $66.3 million (dollar_amount) — Total liabilities as of September 30, 2024.

FAQ

Filing Documents

• cldx-20240930x10q.htm (10-Q) — 1349KB
• cldx-20240930xex31d1.htm (EX-31.1) — 12KB
• cldx-20240930xex31d2.htm (EX-31.2) — 12KB
• cldx-20240930xex32d1.htm (EX-32.1) — 7KB
• 0001410578-24-001766.txt ( ) — 6019KB
• cldx-20240930.xsd (EX-101.SCH) — 33KB
• cldx-20240930_cal.xml (EX-101.CAL) — 39KB
• cldx-20240930_def.xml (EX-101.DEF) — 134KB
• cldx-20240930_lab.xml (EX-101.LAB) — 330KB
• cldx-20240930_pre.xml (EX-101.PRE) — 234KB
• cldx-20240930x10q_htm.xml (XML) — 1247KB

— Financial Information

Part I — Financial Information

Unaudited Financial Statements

Item 1. Unaudited Financial Statements 3 Condensed Consolidated Balance Sheets at September 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 5 Notes to Unaudited Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 34

Controls and Procedures

Item 4. Controls and Procedures 34

— Other Information

Part II — Other Information 35

Risk Factors

Item 1A. Risk Factors 35

Other Information

Item 5. Other Information 35

Exhibits

Item 6. Exhibits 35 Exhibit Index 35

Signatures

Signatures 36 2 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Unaudited Financial Statements

Item 1. Unaudited Financial Statements CELLDEX THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share and per share amounts) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 36,399 $ 34,814 Marketable securities 719,600 388,784 Accounts and other receivables 852 2,628 Prepaid and other current assets 21,991 5,467 Total current assets 778,842 431,693 Property and equipment, net 4,230 4,060 Operating lease right-of-use assets, net 3,170 2,577 Intangible assets 27,190 27,190 Other assets 9,747 107 Total assets $ 823,179 $ 465,627 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,114 $ 3,494 Accrued expenses 28,204 22,029 Current portion of operating lease liabilities 1,379 1,614 Current portion of other long-term liabilities 1,396 3,988 Total current liabilities 32,093 31,125 Long-term portion of operating lease liabilities 1,708 928 Other long-term liabilities 3,473 4,403 Total liabilities 37,274 36,456 Commitments and contingent liabilities Stockholders' equity: Convertible preferred stock, $ .01 par value; 3,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Common stock, $ .001 par value; 297,000,000 shares authorized; 66,344,236 and 55,883,377 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 66 56 Additional paid-in capital 2,288,683 1,823,168 Accumulated other comprehensive income 5,288 3,308 Accumulated deficit ( 1,508,132 ) ( 1,397,361 ) Total stockholders' equity 785,905 429,171 Total liabilities and stockholders' equity $ 823,179 $ 465,627 See accompanying notes to unaudited condensed consolidated financial statements 3 Table of Contents CELLDEX THERAPEUTICS, INC. CONDENSED CONSOLIDATED ST

View Full Filing

View this 10-Q filing on SEC EDGAR